RR&D Research Career Scientist Award Application

RR

• 批准号: 10382219
• 负责人: Machelle T. Pardue
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-01-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10382219
• 关键词: Age; American; Appointment; Area; Award; Basic Science; Biomedical Engineering; Blindness; Climacteric; Clinic; Collaborations; Communities; Detection; Development; Diabetes Mellitus; Diabetic Retinopathy; Disease; Dopamine; Early Diagnosis; Early Intervention; Early treatment; Education; Educational process of instructing; Exercise; Eye; Faculty; Foundations; Functional disorder; Funding; Future; Goals; Growth; Healthcare; Human; IACUC; Imaging technology; Institutes; International; Journals; Laboratories; Laboratory Finding; Leadership; Light; Lighting; Medical; Medicine; Mentors; Mentorship; Methods; Mission; Molecular; Myopia; Neurosciences; Ophthalmology; Pathology; Patients; Physical Exercise; Population; Positioning Attribute; Postdoctoral Fellow; Privatization; Process; Publications; Quality of life; Research; Research Personnel; Research Support; Resources; Retina; Retinal Degeneration; Retinal Diseases; Role; Science; Scientist; Signal Transduction; Silver; Students; Study Section; System; Tissues; Translating; Translations; United States National Institutes of Health; Veterans; Vision; Visual system structure; Woman; age related; base; bench to bedside; career; career development; editorial; field study; graduate student; improved; instructor; interest; lectures; member; neuroprotection; new technology; novel; pre-clinical research; preclinical study; preservation; programs; rehabilitation strategy; research and development; research study; retinal prosthesis; screening; stem; success; symposium; translational study; treatment strategy; undergraduate student; vision science

Dr. Pardue’s research program is centered on developing life-changing treatments for veterans with vision loss. She has made significant contributions in three research areas: a) treatments for retinal degeneration, b) early detection and treatment of diabetic retinopathy, and c) retinal mechanisms of refractive development. Pre-clinical studies from her research program have enhanced our understanding of mechanisms that underlie blinding diseases and advanced new treatment options. Her dual position between the VA and Georgia Tech creates a unique situation to leverage resources and collaborations to move new technologies into the clinic. She is a firm believer that collaborative research is essential to translate results from bench to bedside. This is reflected in over 75% of her 89 publications stemming from collaborations with over 46 different investigators. Moreover, her findings have formed the basis for 3 areas of translational studies to human patients (retinal prosthetics, diabetic retinopathy, and neuroprotection therapies). Dr. Pardue’s dual appointment and research interests create novel opportunities to draw parallels and intersections between different systems and fields of study with the potential for ground-breaking discoveries. Dr. Pardue’s commitment to teaching and mentorship are illustrated by a number of roles. She has lectured to undergraduate and graduate students on the retina and visual system for the last 18 years and been the instructor for 7 courses. Dr. Pardue has a strong interest in professional development and has organized and taught courses for post-docs and graduate students on this topic at the VA, Emory, and Georgia Tech, as well as at international conferences. In addition, she actively supports women in science at the graduate and junior faculty levels through institutional and international programs. Dr. Pardue has mentored 5 VA Career Development Awardees (CDAs). Over 80% of the students that she has mentored have continued on in medicine or science. Dr. Pardue has consistently served the scientific community throughout her career. Specific to the VA, Dr. Pardue chaired the IACUC Committee from 2004-2008 and has chaired the R&D Committee for the last ten years (2008-date). She assisted with two successful renewal cycles of the Atlanta VA Rehab Center. As the Associate Director of Scientific Projects, she directed the internal review process of all Rehab Center submissions, increasing the funding rate to 20% for Merits and 42% for CDAs. She currently serves as the interim Associate Director of the CVNR. She also serves on the Advisory Board for the Atlanta VA non-profit foundation (AREF). On the international level, she has served on several committees for ARVO and was awarded their prestigious Silver Fellow Award in May 2016. Dr. Pardue has served on many study sections from NIH, VA, and various national and international private foundations. She currently serves as a regular member of NIH Neuroscience and Ophthalmic Imaging Technologies (NOIT) study section. Her contributions and leadership in the field was recognized in 2017 by induction as a fellow into the American Institute of Medical and Biological Engineers (AIMBE). Dr. Pardue’s future goals are to 1) develop new rehabilitation strategies for blinding diseases, 2) identify the earliest signs of diabetic retinopathy and determine early interventions to slow the progression of vision loss, and 3) determine the role of dopamine in refractive eye growth. These goals are grounded in the results from her laboratory over the last several years, including the increased number of publications in high impact journals. Based on prior success, she anticipates the development of new treatment strategies. Translation of these findings from the laboratory to the clinic will be facilitated by her collaborations within the CVNR and clinicians at the VA. Thus, these projects support both the common theme of understanding and treating retinal disease to prolong functional vision and the VA mission of improving healthcare for veterans.

Pardue博士的研究计划集中于为退伍军人开发改变生活的治疗方法 视力丧失。她在三个研究领域做出了重大贡献： 变性，b）早期检测和信任​​糖尿病性视网膜病，c）视网膜折射机制 她的研究计划的临床前研究增强了我们的理解 盲目疾​​病和高级新治疗方案的机制。 VA和Georgia Tech创造了一个独特的情况，以利用资源和协作来移动新的新新型 诊所的技术。 从长凳到床边。 超过46位不同的研究人员。 对人类患者（视网膜假肢，糖尿病性视网膜病和神经保护疗法）。 约会和研究兴趣创造了新的机会，以吸引并行的相互作用 不同的系统和研究领域，具有开创性发现的潜力。 帕德博士对教学和指导的承诺有许多角色。 在过去的18年中，在视网膜和视觉系统上讲授地下和研究生， 是7门课程的讲师。 在弗吉尼亚州和乔治亚州的该主题上为博士后和研究生的课程组织和教授课程 技术以及在国际会议上。 通过工厂和国际计划的研究生和初级教师水平。 VA职业发展获奖者（CDA）。 医学或科学。 帕杜博士在整个职业生涯中一直为科学界服务。 Pardue博士于2004年至2008年担任IACC委员会主席，并主持研发委员会的最后十名 年（2008年），她协助了亚特兰大弗吉尼亚州康复中心的两个成功的续约周期。 她的科学项目副主任，她主任所有康复中心的审查流程 提交，案情的资金率提高到20％，CDA的资金率为42％。 CVNR的临时副主任。 基金会（AREF）。 2016年5月颁发了著名的Sillow奖。 来自NIH，弗吉尼亚州以及各种国家和国际私人基金会。 NIH神经科学和眼科成像技术（NOIT）研究部分 该领域的领导在2017年被指示为美国研究所的同胞 医学和生物工程师（AIMBE）。 帕杜博士的未来目标是1）制定新的康复策略以盲目疾病，2）确定 糖尿病性视网膜病的伯爵体迹象并确定早期干预措施，以减缓视力进展 3）确定多巴胺在折射率生长中的作用。 从过去几年中 期刊 这些从实验室的发现将通过与CVNR和 弗吉尼亚州的临床医生。 疾病延长功能视力和改善退伍军人医疗保健的VA使命。